Beschreibung
Fluconazole has minimal effect on pravastatin exposure because pravastatin is not significantly metabolised by CYP enzymes; the interaction is pharmacokinetically unimportant in most patients.
Mechanismus
Unlike most statins, pravastatin relies on renal and biliary excretion rather than CYP3A4 metabolism; fluconazole's CYP inhibition does not substantially affect pravastatin clearance.
Klinische Bedeutung
Pharmacokinetic studies confirm no clinically significant increase in pravastatin AUC with fluconazole; no cases of myopathy attributable to this combination have been reported.
Maßnahmen
No dose adjustment required; this combination is generally preferred over other statin-azole combinations.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.